Humacyte Plans to Release First Quarter Financial Results
Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology firm, is gearing up to reveal its first quarter financial results for the period ending March 31, 2025. This much-anticipated release will take place on May 13, 2025, with an insightful webcast and conference call scheduled for 8:30 a.m. Eastern Time. Investors and interested parties are encouraged to tune in to understand the company's financial standing and strategic direction.
Key Details for Investors
The conference call will allow executives to provide both financial insights and updates on corporate developments. It's a great opportunity for stakeholders to engage directly with Humacyte's management team. For those looking to listen in, the call can be accessed using specific numbers: U.S. investors can dial 1-877-704-4453, while international investors can join via 1-201-389-0920. Be sure to have the Conference ID of 13753487 handy for seamless entry.
Webcast Accessibility
Prior to the conference call, the webcast will be available 15 minutes ahead of the start time, ensuring that all participants can connect without issues. A recorded version will be posted on the company’s investor relations section after the live event concludes, allowing anyone who missed the call to catch up on the information shared during the session.
About Humacyte and Its Innovations
Humacyte is renowned for its focus on developing universally implantable, bioengineered human tissues, which have the potential to revolutionize the medical field. The company’s mission is to create acellular tissues that can effectively treat a variety of diseases, traumatic injuries, and chronic conditions. Their flagship product, the acellular tissue engineered vessel (ATEV), recently received FDA approval for specific vascular trauma applications, showcasing its innovative approach to medical interventions.
Clinical Trials and Designations
Currently, Humacyte is conducting late-stage clinical trials for the ATEV targeting vital areas such as arteriovenous (AV) access for hemodialysis and addressing peripheral artery disease. The ATEV has garnered multiple designations from the FDA, including the Regenerative Medicine Advanced Therapy (RMAT) designation, indicating its significant potential benefits. Furthermore, it also holds the distinction of receiving fast track designation from the FDA, underscoring the urgent need for advanced treatments in this area.
Commitment to Transforming Healthcare
Humacyte plans to broaden its research and development efforts across various applications, with active preclinical trials exploring coronary artery bypass grafts, pediatric heart surgeries, and even treatment avenues for type 1 diabetes. Their innovative uses indicate a commitment to advancing healthcare through breakthrough biotechnology solutions.
Contact Information for Investors
For investors looking to connect with Humacyte, Joyce Allaire from LifeSci Advisors LLC can be reached at +1-617-435-6602 or via email at jallaire@lifesciadvisors.com. Investors should take advantage of this opportunity to learn more about the innovative work Humacyte is pursuing and its implications for medical treatments in the near future.
Frequently Asked Questions
What is the date and time of Humacyte's financial results release?
The financial results will be released on May 13, 2025, at 8:30 a.m. Eastern Time.
How can investors participate in the conference call?
Investors can dial 1-877-704-4453 for U.S. participants and 1-201-389-0920 for international callers using the Conference ID: 13753487.
Where can I access the webcast?
The webcast will be available 15 minutes before the start of the call on Humacyte’s investor relations page and will remain accessible for 30 days post-event.
What does Humacyte specialize in?
Humacyte specializes in developing bioengineered tissues and organ systems intended to treat a variety of medical conditions and to enhance patient care.
Who can I contact for investor relations queries?
For investor inquiries, reach out to Joyce Allaire at LifeSci Advisors LLC or email her at jallaire@lifesciadvisors.com.
